Celldex Therapeutics Common Stock Net 2010-2025 | CLDX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Celldex Therapeutics common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Celldex Therapeutics common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$241.7B
Amgen (AMGN)	$155.8B
Gilead Sciences (GILD)	$149.1B
Vertex Pharmaceuticals (VRTX)	$101.5B
Bristol Myers Squibb (BMY)	$97.4B
CSL (CSLLY)	$86.1B
GSK (GSK)	$79.8B
Regeneron Pharmaceuticals (REGN)	$59.5B
Alnylam Pharmaceuticals (ALNY)	$56.7B
Argenex SE (ARGX)	$39.6B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$26B
Royalty Pharma (RPRX)	$20.5B
Biogen (BIIB)	$19.8B
Incyte (INCY)	$16.8B
Illumina (ILMN)	$15.5B
Genmab (GMAB)	$14.5B
Genmab (GNMSF)	$14.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.5B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Bio-Techne Corp (TECH)	$8.6B
Exact Sciences (EXAS)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B
Halozyme Therapeutics (HALO)	$8B